---
document_datetime: 2025-11-23 08:03:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pumarix.html
document_name: pumarix.html
version: success
processing_time: 0.1081032
conversion_datetime: 2025-12-28 19:09:20.602403
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pumarix

[RSS](/en/individual-human-medicine.xml/66371)

##### Withdrawn

This medicine's authorisation has been withdrawn

pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Pumarix](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 11 February 2015, the European Commission withdrew the marketing authorisation for Pumarix (pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)) in the European Union (EU). The withdrawal was requested by the marketing authorisation holder, GlaxoSmithKline Biologicals, which notified the European Commission that it did not intend to maintain the marketing authorisation for commercial reasons.

Pumarix was granted a marketing authorisation in the EU on 4 March 2011 for prevention of influenza (flu) in an officially declared pandemic situation. The marketing authorisation was valid for a 5-year period, subject to subsequent renewals. Pumarix has never been marketed in the EU, and was intended to be used in an officially declared influenza pandemic following the identification and, if appropriate, the inclusion of the influenza strain causing the pandemic into the vaccine. Another product, Adjupanrix (pandemic influenza vaccine A/H5N1, split virion, inactivated, adjuvanted) is authorised in the EU for prevention of influenza in an officially declared pandemic situation, and can be used instead of Pumarix. The marketing authorisation holder, GlaxoSmithKline Biologicals, will maintain the marketing authorisation for Adjupanrix.

The European Public Assessment Report (EPAR) for Pumarix is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Pumarix : EPAR - Summary for the public

English (EN) (531.02 KB - PDF)

**First published:** 05/04/2011

**Last updated:** 17/03/2015

[View](/en/documents/overview/pumarix-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-267)

български (BG) (692.36 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/bg/documents/overview/pumarix-epar-summary-public_bg.pdf)

español (ES) (529.54 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/es/documents/overview/pumarix-epar-summary-public_es.pdf)

čeština (CS) (600.19 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/cs/documents/overview/pumarix-epar-summary-public_cs.pdf)

dansk (DA) (595.85 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/da/documents/overview/pumarix-epar-summary-public_da.pdf)

Deutsch (DE) (528.89 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/de/documents/overview/pumarix-epar-summary-public_de.pdf)

eesti keel (ET) (533.1 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/et/documents/overview/pumarix-epar-summary-public_et.pdf)

ελληνικά (EL) (650.19 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/el/documents/overview/pumarix-epar-summary-public_el.pdf)

français (FR) (534.38 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/fr/documents/overview/pumarix-epar-summary-public_fr.pdf)

italiano (IT) (531.26 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/it/documents/overview/pumarix-epar-summary-public_it.pdf)

latviešu valoda (LV) (603.03 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/lv/documents/overview/pumarix-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (557.85 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/lt/documents/overview/pumarix-epar-summary-public_lt.pdf)

magyar (HU) (591.33 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/hu/documents/overview/pumarix-epar-summary-public_hu.pdf)

Malti (MT) (599.66 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/mt/documents/overview/pumarix-epar-summary-public_mt.pdf)

Nederlands (NL) (527.64 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/nl/documents/overview/pumarix-epar-summary-public_nl.pdf)

polski (PL) (598.29 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/pl/documents/overview/pumarix-epar-summary-public_pl.pdf)

português (PT) (526.78 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/pt/documents/overview/pumarix-epar-summary-public_pt.pdf)

română (RO) (559.5 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/ro/documents/overview/pumarix-epar-summary-public_ro.pdf)

slovenčina (SK) (595.73 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/sk/documents/overview/pumarix-epar-summary-public_sk.pdf)

slovenščina (SL) (586.97 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/sl/documents/overview/pumarix-epar-summary-public_sl.pdf)

Suomi (FI) (533.09 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/fi/documents/overview/pumarix-epar-summary-public_fi.pdf)

svenska (SV) (525.66 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/sv/documents/overview/pumarix-epar-summary-public_sv.pdf)

## Product information

Pumarix : EPAR - Product Information

English (EN) (1000.31 KB - PDF)

**First published:** 05/04/2011

**Last updated:** 17/03/2015

[View](/en/documents/product-information/pumarix-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-234)

български (BG) (1.86 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/bg/documents/product-information/pumarix-epar-product-information_bg.pdf)

español (ES) (1015.8 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/es/documents/product-information/pumarix-epar-product-information_es.pdf)

čeština (CS) (1.56 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/cs/documents/product-information/pumarix-epar-product-information_cs.pdf)

dansk (DA) (989.86 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/da/documents/product-information/pumarix-epar-product-information_da.pdf)

Deutsch (DE) (1022.96 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/de/documents/product-information/pumarix-epar-product-information_de.pdf)

eesti keel (ET) (1.01 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/et/documents/product-information/pumarix-epar-product-information_et.pdf)

ελληνικά (EL) (1.94 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/el/documents/product-information/pumarix-epar-product-information_el.pdf)

français (FR) (1.01 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/fr/documents/product-information/pumarix-epar-product-information_fr.pdf)

hrvatski (HR) (1.07 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/hr/documents/product-information/pumarix-epar-product-information_hr.pdf)

íslenska (IS) (1017.39 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/is/documents/product-information/pumarix-epar-product-information_is.pdf)

italiano (IT) (1009.37 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/it/documents/product-information/pumarix-epar-product-information_it.pdf)

latviešu valoda (LV) (1.62 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/lv/documents/product-information/pumarix-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.05 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/lt/documents/product-information/pumarix-epar-product-information_lt.pdf)

magyar (HU) (1.58 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/hu/documents/product-information/pumarix-epar-product-information_hu.pdf)

Malti (MT) (1.65 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/mt/documents/product-information/pumarix-epar-product-information_mt.pdf)

Nederlands (NL) (1 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/nl/documents/product-information/pumarix-epar-product-information_nl.pdf)

norsk (NO) (993.36 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/no/documents/product-information/pumarix-epar-product-information_no.pdf)

polski (PL) (1.54 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/pl/documents/product-information/pumarix-epar-product-information_pl.pdf)

português (PT) (998.18 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/pt/documents/product-information/pumarix-epar-product-information_pt.pdf)

română (RO) (1.14 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/ro/documents/product-information/pumarix-epar-product-information_ro.pdf)

slovenčina (SK) (1.6 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/sk/documents/product-information/pumarix-epar-product-information_sk.pdf)

slovenščina (SL) (1.55 MB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/sl/documents/product-information/pumarix-epar-product-information_sl.pdf)

Suomi (FI) (1010.24 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/fi/documents/product-information/pumarix-epar-product-information_fi.pdf)

svenska (SV) (998.99 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/sv/documents/product-information/pumarix-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** P46/0016 28/02/2014

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pumarix : EPAR - All Authorised presentations

English (EN) (506.53 KB - PDF)

**First published:** 05/04/2011

**Last updated:** 17/03/2015

[View](/en/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-313)

български (BG) (564.77 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/bg/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_bg.pdf)

español (ES) (507.55 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/es/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_es.pdf)

čeština (CS) (554.2 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/cs/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (508.21 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/da/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (472.1 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/de/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (472.43 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/et/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (560.58 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/el/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_el.pdf)

français (FR) (507.54 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/fr/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (509.07 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/is/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_is.pdf)

italiano (IT) (505.99 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/it/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (552.38 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/lv/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (540.26 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/lt/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (548.91 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/hu/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (561 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/mt/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (473.05 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/nl/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (472.2 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/no/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_no.pdf)

polski (PL) (557.67 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/pl/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_pl.pdf)

português (PT) (472.3 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/pt/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_pt.pdf)

română (RO) (542.51 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/ro/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (556.72 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/sk/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (518.95 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/sl/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (467.38 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/fi/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (472.7 KB - PDF)

**First published:**

05/04/2011

**Last updated:**

17/03/2015

[View](/sv/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pumarix Active substance pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) International non-proprietary name (INN) or common name pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) Therapeutic area (MeSH)

- Influenza, Human
- Immunization
- Disease Outbreaks

Anatomical therapeutic chemical (ATC) code J07BB02

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Prophylaxis of influenza in an officially declared pandemic situation.

Pandemic-influenza vaccine should be used in accordance with official guidance.

## Authorisation details

EMA product number EMEA/H/C/001212

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

GlaxoSmithKline Biologicals S.A.

Rue de l'Institut, 89

Marketing authorisation issued 04/03/2011 Withdrawal of marketing authorisation 11/02/2015 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pumarix : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (569.11 KB - PDF)

**First published:** 27/02/2012

**Last updated:** 17/03/2015

[View](/en/documents/procedural-steps-after/pumarix-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Pumarix-H-C-1212-P46-0016 : EPAR - Assessment Report

Adopted

Reference Number: EMA/711988/2014

English (EN) (1.33 MB - PDF)

**First published:** 18/11/2014

**Last updated:** 17/03/2015

[View](/en/documents/variation-report/pumarix-h-c-1212-p46-0016-epar-assessment-report_en.pdf)

Pumarix-H-C-1212-PSUV-0009 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/265942/2014

English (EN) (524.86 KB - PDF)

**First published:** 13/05/2014

**Last updated:** 17/03/2015

[View](/en/documents/scientific-conclusion/pumarix-h-c-1212-psuv-0009-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Pumarix : EPAR - Public assessment report

Adopted

English (EN) (2.24 MB - PDF)

**First published:** 05/04/2011

**Last updated:** 17/03/2015

[View](/en/documents/assessment-report/pumarix-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pumarix

Adopted

Reference Number: EMA/CHMP/692469/2010

English (EN) (515.53 KB - PDF)

**First published:** 19/11/2010

**Last updated:** 17/03/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pumarix_en.pdf)

#### More information on Pumarix

- [EMEA-000178-PIP01-07-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000178-pip01-07-m04)

**This page was last updated on** 17/03/2015

## Share this page

[Back to top](#main-content)